Santhera Pharmaceuticals Holding AG Long Term Debt

Santhera Pharmaceuticals Holding AG (SPHDF) currently reports a long-term debt of $30M as of June 2026. That compares with $61M in the prior-year period — down 50.5% year over year. Use the charts on this page to explore Santhera Pharmaceuticals Holding AG's long-term debt history and peer comparisons.

Santhera Pharmaceuticals Holding AG's long-term debt decreased from $61M to $30M — a 50.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Santhera Pharmaceuticals Holding AG reported $30M in long-term debt as of June 2026. That compares with $61M in the prior-year period — down 50.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $30M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Santhera Pharmaceuticals Holding AG, and consider following SPHDF for alerts when major investors trade the stock.

Santhera Pharmaceuticals Holding AG is classified in the Healthcare sector. On long-term debt, it currently shows $30M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPHDF with unrelated industries.